Marshall Wace, LLP Adverum Biotechnologies, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.5 - $2.33 $355,996 - $552,981	237,331 New	237,331 $355,000
Q4 2022 Feb 14, 2023	SELL	$0.54 - $10.3 $88,743 - $1.69 Million	-164,340 Reduced 32.5%	341,397 $198,000
Q3 2022 Nov 14, 2022	BUY	$0.96 - $9.68 $485,507 - $4.9 Million	505,737 New	505,737 $481,000
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $253,407 - $401,742	-206,022 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $358,478 - $494,452	206,022 New	206,022 $364,000
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $3.32 Million - $5.14 Million	-358,166 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $113,652 - $164,703	-11,550 Reduced 3.12%	358,166 $3.88 Million
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $3.81 Million - $8 Million	369,716 New	369,716 $3.81 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.